Reishi (Ganoderma lucidum) is one of the most extensively studied medicinal mushrooms in the world. While much of the attention has focused on its immune-modulating and adaptogenic properties, a growing body of research is examining whether reishi may also play a role in supporting healthy blood sugar metabolism. This article reviews what the current evidence shows, the compounds believed to be responsible, and what is still unknown.
Reishi’s Bioactive Compounds and Metabolic Relevance
Reishi contains two primary classes of bioactive compounds relevant to blood sugar research: polysaccharides (including beta-glucans and proteoglycans) and triterpenoids (such as ganoderic acids). These compounds appear to work through different mechanisms, and researchers have been investigating both independently and in combination.
Triterpenoids found in reishi have been studied for their potential influence on insulin sensitivity and inflammatory signaling pathways. A 2023 review published in Foods noted that reishi triterpenoids demonstrated the ability to improve insulin sensitivity and reduce blood glucose levels in animal models of diabetes, while polysaccharides from the same species showed effects on glucose metabolism in models of obesity-induced metabolic dysfunction.[1]
It is important to note that animal model findings do not always translate directly to humans, and the doses used in preclinical studies often differ substantially from what is available in commercial supplements.
Clinical Evidence: What Human Trials Show
Human clinical data on reishi and glycemic control is limited but growing. A 2025 randomized clinical trial published in Clinical Diabetes compared the effects of Ganoderma lucidum and kombucha on glycemic markers in patients with type 2 diabetes. Participants in the G. lucidum group experienced significant reductions in fasting blood glucose, 2-hour postprandial glucose, and HbA1c compared to baseline. The authors noted that the magnitude of effect was comparable between the two intervention groups, with no statistically significant difference between them. They also emphasized that further studies examining different doses and longer follow-up periods are needed to clarify optimal use.[2]
This trial represents one of the more rigorous recent contributions to the clinical literature on reishi and blood sugar, though the sample size and intervention duration remain modest. Larger, longer trials with standardized extracts would be needed before firm conclusions can be drawn.
Proteoglycans and Lipid Metabolism
Beyond polysaccharides and triterpenoids, researchers have investigated specific reishi-derived proteoglycans. A 2023 study published in Lipids and Health Disease examined FYGL, a hyperbranched proteoglycan isolated from the G. lucidum fruiting body, in a mouse model of obesity-induced diabetes. The compound appeared to modulate fatty acid metabolism, reduce insulin resistance-related gene expression, and activate the AMPK signaling pathway, a key regulator of cellular energy balance. The authors suggested FYGL may represent a promising candidate for further research into metabolic disorder management.[3]
Again, this is preclinical data. The translation to human outcomes requires clinical validation.
Polysaccharide Peptides and Vascular Health in Diabetes
One additional mechanism that has received research attention involves reishi polysaccharide peptides (PsP) and their potential effects on vascular health in the context of diabetes. Elevated blood glucose can contribute to endothelial damage over time, and a 2019 study in Vascular Health and Risk Management explored whether PsP from G. lucidum might support vascular repair. The study, conducted in a rodent model of type 2 diabetes, found that PsP administration was associated with reduced insulin resistance, lower triglycerides and total cholesterol, and improved endothelial progenitor cell activity in a dose-dependent pattern.[4]
The authors noted the need for further clinical trials before commercial or therapeutic applications could be supported.
Potential Mechanisms: A Summary
Based on the available literature, researchers have proposed several mechanisms by which reishi compounds may influence blood sugar regulation:
- Alpha-glucosidase inhibition: Some reishi polysaccharides and triterpenoids appear to inhibit enzymes involved in carbohydrate digestion, potentially slowing glucose absorption.
- Insulin sensitization: Triterpenoids may interact with insulin signaling pathways in ways that research suggests could improve cellular glucose uptake.
- AMPK pathway activation: Proteoglycans from reishi have been studied for their ability to activate AMPK, a cellular energy sensor involved in glucose and fat metabolism.
- Inflammatory modulation: Chronic low-grade inflammation is closely associated with insulin resistance; reishi’s anti-inflammatory properties may contribute indirectly to metabolic outcomes.
These mechanisms are largely derived from in vitro and animal research, and the relative contribution of each in human physiology has not been established.
Considerations and Safety
For individuals managing blood sugar with prescribed medications, reishi supplements warrant careful consideration. Research suggests that reishi may have additive effects alongside antidiabetic drugs, which could theoretically increase the risk of hypoglycemia. Anyone managing diabetes or prediabetes with medication should consult a healthcare provider before introducing any mushroom supplement.
Reishi supplements vary considerably in quality, extract type, and bioactive compound concentration. If you are evaluating a reishi product, understanding how to interpret supplement labels, including beta-glucan percentages and extract ratios, is an important first step. Our guide to Reishi Spores vs Fruiting Body covers these distinctions in detail.
What the Evidence Does Not Yet Show
The existing human clinical data on reishi and blood sugar management is promising but preliminary. Most trials have been small, short in duration, and conducted in populations with existing type 2 diabetes. There is currently insufficient evidence to recommend reishi as a standalone intervention for blood sugar control, and no regulatory body has approved it for this purpose.
Research directions that may yield more clarity in coming years include standardized extract comparisons, dose-response studies in prediabetic populations, and longer-term trials examining effects on HbA1c and fasting insulin.
Conclusion
Ganoderma lucidum contains a diverse array of bioactive compounds that have shown metabolic effects in preclinical models, and early clinical research suggests it may support glycemic markers in individuals with type 2 diabetes. The mechanisms are plausible and grounded in biochemistry, but the human evidence base remains limited. Reishi may be one component of a broader lifestyle approach for metabolic health, but it should not replace evidence-based medical treatment.
As with all functional mushroom research, the quality of the supplement, the form of extract used, and the presence of standardized bioactive compounds all matter significantly when evaluating potential effects.
References
- [1] Ekiz E, et al. Exploring the Potential Medicinal Benefits of Ganoderma lucidum: From Metabolic Disorders to Coronavirus Infections. Foods. 2023;12(7):1512. PMID: 37048331
- [2] Yekefallah L, et al. Comparing the Effects of Ganoderma lucidum and Kombucha Mushrooms on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. Clin Diabetes. 2025;43(5):813-822. PMID: 41438309
- [3] Wang Y, et al. Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum. Lipids Health Dis. 2023;22(1):120. PMID: 37553709
- [4] Heriansyah T, et al. Polysaccharide peptide (PsP) Ganoderma lucidum: a potential inducer for vascular repair in type 2 diabetes mellitus model. Vasc Health Risk Manag. 2019;15:419-427. PMID: 31632046
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Reishi mushroom supplements are not approved to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting any supplement, especially if you are managing a medical condition or taking prescription medications.
